Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Genitourin Cancer. 2009 Aug;7(2):E37-8. doi: 10.3816/CGC.2009.n.020.

Reversal of docetaxel resistance with bevacizumab and thalidomide.

Author information

1
DDOP/OODP/CDER, Food and Drug Administration, Silver Spring, MD, USA.

Abstract

Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

PMID:
19692321
PMCID:
PMC3438454
DOI:
10.3816/CGC.2009.n.020
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center